Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology-Reference-Cited by-同舟云学术

Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology

Published:2019-09-09 Issue:39 Volume:141 Page:15700-15709
ISSN:0002-7863
Container-title:Journal of the American Chemical Society
language:en
Short-container-title:J. Am. Chem. Soc.

Author:

Da Chenxiao¹,Zhang Dehui¹,Stashko Michael¹,Vasileiadi Eleana²,Parker Rebecca E.²,Minson Katherine A.²,Huey Madeline G.²,Huelse Justus M.²,Hunter Debra,Gilbert Thomas S. K.^ORCID,Norris-Drouin Jacqueline¹,Miley Michael,Herring Laura E.^ORCID,Graves Lee M.^ORCID,DeRyckere Deborah²,Earp H. Shelton,Graham Douglas K.²,Frye Stephen V.¹^ORCID,Wang Xiaodong¹^ORCID,Kireev Dmitri¹^ORCID

Affiliation:

1. Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7363, United States

2. Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, and Department of Pediatrics, Emory University, Atlanta, Georgia 30322, United States

Funder

National Cancer Institute

University of North Carolina at Chapel Hill

Publisher

American Chemical Society (ACS)

Subject

Colloid and Surface Chemistry,Biochemistry,General Chemistry,Catalysis

Link

https://pubs.acs.org/doi/pdf/10.1021/jacs.9b08660

Reference41 articles.

1. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?

2. Kinase Drug Discovery – What’s Next in the Field?